Investigating Responses to Nivolumab and Ipilimumab in Advanced RCC

July 8, 2020

Rana R. McKay, MD, discusses the phase 2 OMNIVORE trial of nivolumab and ipilimumab in patients with advanced renal cell carcinoma.

Rana R. McKay, MD, assistant professor of Medicine and medical oncologist at the University of California, San Diego, discusses the phase 2 OMNIVORE trial (NCT03203473) of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced renal cell carcinoma.

The first part of the trial looked at the efficacy of induction nivolumab, which encompassed the patient’s responses to nivolumab in the first 6 months prior to their arm allocation, according to McKay. The objective response rate was about 14%, with no complete responses (CRs), 9 confirmed partial responses (PRs), and 3 unconfirmed PRs.

In arm A, 5 patients or 45% remained off nivolumab at 1 year after treatment discontinuation. There was 1 patient with CR after about 17 months of treatment.

The rate of conversion to CR or PR among patients in arm B, who had stable or progressive disease and received the combination therapy, was low at 4%, McKay explains. Two patients converted to a PR, and there were no CRs in this arm. Those 2 patients had been previously treated and had progressive disease as their best response to the nivolumab induction.

At the time of the data cutoff, 54 out of 57 patients in arm B had discontinued treatment. The primary reason for this was disease progression. The 18-month overall survival for all patients on this trial was 79%, and the median had not been reached, according to McKay.

<< View more resources and information regarding renal cell carcinoma